Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 14/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | ADH1B | P00325 | 1/20 | 0.32 |
| ▸ | ADH1C | P00326 | 1/20 | 0.32 |
| ▸ | ADH1A | P07327 | 1/20 | 0.32 |
| ▸ | ADH4 | P08319 | 1/20 | 0.32 |
| ▸ | ADH7 | P40394 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23275869 | 1.00 | TRPV3 (0.38) | TRPV3SIGMAR1ADH1BADH1CADH1A | |
| SCHEMBL23275875 | 0.79 | SIGMAR1 (0.42) | SIGMAR1ADH1BADH1CADH1AADH4 | |
| SCHEMBL23275873 | 0.79 | SIGMAR1 (0.42) | SIGMAR1ADH1BADH1CADH1AADH4 | |
| SCHEMBL19098393 | 0.77 | TRPV3 (0.34) | TRPV3 | |
| SCHEMBL19064104 | 0.77 | SLC6A1 (0.37) | TRPV3 | |
| SCHEMBL19063889 | 0.77 | SLC6A1 (0.37) | TRPV3 | |
| SCHEMBL19122994 | 0.77 | SLC6A1 (0.37) | TRPV3 | |
| SCHEMBL19064149 | 0.77 | SLC6A1 (0.37) | TRPV3 | |
| SCHEMBL19063732 | 0.77 | SLC6A1 (0.37) | TRPV3 | |
| SCHEMBL19063730 | 0.77 | SLC6A1 (0.37) | TRPV3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114269741-A | Cycloalkyl and heterocycloalkyl inhibitors, and preparation method and application thereof | 苏州泽璟生物制药股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| WO-2021078312-A1 | CYCLOALKYL AND HETERO-CYCLOALKYL INHIBITORS, PREPARATION METHODS THEREFOR, AND USE THEREOF | 苏州泽璟生物制药股份有限公司 | 2021-04-29 | — | — | WO | disclosed |
| WO-2021078285-A1 | CYCLOALKYL-BASED AND HETEROCYCLOALKYL-BASED INHIBITORS, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州泽璟生物制药股份有限公司 | 2021-04-29 | — | — | WO | disclosed |
| CN-112694475-A | Cycloalkyl and heterocycloalkyl inhibitors, and preparation method and application thereof | 苏州泽璟生物制药股份有限公司 | 2021-04-23 | — | — | CN | disclosed |
| US-20210054040-A1 | NOVEL IL-15 CONJUGATES AND USES THEREOF | Synthorx, Inc. (US) | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210054040-A1 | NOVEL IL-15 CONJUGATES AND USES THEREOF | IL15, IL15RA, IL5 | TRPV3 4783/4885SIGMAR1 2991/4885ADH1B 2157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.